Hereditary thrombotic thrombocytopenic purpura mimicking immune thrombocytopenia was revealed by miscarriage—novel compound heterozygous mutations in hTTP Authors: Ruiqing Zhou, Jiahuan Wang, Ahui Wang, Shunqing Wang, Yumiao Li, Shilin Xu, Wenjian Mo Published: 2024 ABSTRACT We report a case of early-onset hereditary thrombotic thrombocytopenic purpura in a 16-year-old girl who suffered from thrombocytopenia and was misdiagnosed with immune thrombocytopenia for years until two failed gestations finally revealed the underlying cause. The novel compound heterozygous mutation c.2865G > A:p.Trp955X and c.721delG: p.Gly241fs in the ADAMTS13 gene were identified and are predicted to be associated with this disease. The patient responded to plasma therapy, including plasma infusion and plasma exchange, but renal dysfunction may be longstanding. Introduction Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare and life-threatening blood disorder caused by compound heterozygous or homozygous mutations in the ADAMTS13 gene (encoding a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) [1]. ADAMTS13 is a vital enzyme consisting of 1427 amino acids encoded by 29 exons on chromosome 9q34 [2]. As a specific VWF-cleaving protease, ADAMTS13 cleaves ultralarge vWF (UL-VWF) multimers. In the absence of ADAMTS13, UL-VWF multimers adhere to platelets and promote the development of microvascular thrombosis [3]. TTP is characterized by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA), fever, renal failure and neurologic deficits. ADAMTS13 deficiency is necessary but not always sufficient to cause acute clinical manifestations, and triggering factors may be needed. Pregnancy, infection or inflammation are needed to induce an acute episode of TTP [1, 4, 5]. An acute episode of TTP may present the classic pentad of the abovementioned symptoms, whereas in remission, patients may present as asymptomatic or solely with thrombocytopenia, which makes achieving an early and accurate diagnosis difficult. Here, we report an hTTP case that was misdiagnosed as immune thrombocytopenia (ITP) for several years and was ultimately revealed by two failed gestations. Two novel mutations in ADAMTS13 were found in this patient. Case description A female patient presented with spot ecchymosis on her extremities without injury when she was 16. Laboratory examinations revealed that her platelet (PLT) count was 14 × 109/L, and a total of 695 megakaryocytes were observed in the specimen, with a decreased thrombocytopenic megakaryocytes count (5/50). Based on the above evidence, this patient was diagnosed with ITP and was treated with glucocorticoids (methylprednisolone 500 mg/day iv for 4 days and then oral prednisone 50 mg/day). Her platelet count returned to 50 × 109/L but decreased as the dosage of prednisone decreased. In place of prednisone, cyclosporin A (CsA) was administered, and her platelet count reached 100–200 × 109/L. The platelet count decreased when she became pregnant 5 years later. She had to undergo abortion at the 8th week of gestation because of thrombocytopenia. After abortion and drug treatment, including corticosteroids and CsA, the patient’s blood cell count was generally maintained within normal limits until she became pregnant again. During pregnancy, her platelet count ranged from 27 to 40 × 109/L without medical intervention. Unfortunately, the foetus was found to have died in utero at the age of 26 weeks. No abnormalities were detected in the labor-inducing tissue by CNV-seq or karyotype analysis, but placental biopsy was not performed. The failure of these two pregnancies prompted us to perform a comprehensive assessment. In addition to thrombocytopenia and anaemia, her percentage of reticulocytes was especially high (7.1%), and her hapto-globin level was below the lower limit of detection. Schistocytes were observed in her peripheral blood and bone marrow. Her LDH level was 2 times greater than the normal value, whereas her AST and bilirubin levels remained normal. Her serum creatinine (Cr) and urinary protein levels were also higher than normal. Echo enhancement of the renal parenchyma was observed on colour Doppler ultrasound of the urinary system. Autoantibodies, especially anticardiolipin antibodies, and lupus anticoagulant levels were tested for, and none of those results indicated that the patient had an autoimmune disease. Thus, the hypothesis that the patient had TTP or HUS was proposed. Severe deficiency in ADAMTS13 activity was detected (< 0.1% activity), and the ADAMTS13 inhibitor test was negative. The vWF antigen level of was normal. Gene analysis of ADAMTS13 revealed a nonsense mutation, p.Trp955X, in exon 23 and a frameshift mutation, p.Gly241fs, in exon 7. The patient was finally diagnosed with hTTP.When fresh frozen plasma transfusion (FFP) (10 ml/kg) and plasma exchange (PE) (40 ml/kg) were performed [6–9], her platelet count and haemoglobin level returned to within normal limits, and the Cr and urinary protein levels declined (Figs. 1 and 2). Ultrasonography of her renal system showed normal echo results. Even though the patient’s ADAMTS13 activity returned to baseline 2 weeks after a 600 ml plasma infusion, her platelet count remained normal. Consequently, the patient is now receiving a 400 ml FFP infusion every 2 weeks. Fig. 1ADAMTS13 activity and clinical data vary after plasma infusion and plasma exchange treatments ADAMTS13 activity and clinical data vary after plasma infusion and plasma exchange treatments Fig. 2Renal function is improved after plasma infusion and plasma exchange Renal function is improved after plasma infusion and plasma exchange With respect to her family history, the patient denied the presence of consanguineous marriages. ADAMTS13 activity and gene analysis of the family are shown in Fig. 3. The proband inherited the mutation p.Trp955X in exon 23 from her father, whose ADAMTS13 activity is 47.77% without clinical manifestations. Her mother gave birth to 4 children, one of whom died from unknown causes within the first month. Her mother had an elevated bilirubin level after giving birth to her fourth child and died in a car accident five years later. Whether anaemia or neurologic deficits were involved in the accident, as she was believed to carry a mutation in ADAMTS13, remains unknown. The patient’s sister had 2 children without related complications during pregnancy. The sister’s ADAMTS13 activity was 56.46%, and the mutation p.Gly241fs in exon 7 was verified. ADAMTS13 activity was intact in the patient’s brother, and neither mutation was detected in his blood sample. Written informed consent was obtained from all of the participants. Fig. 3Pedigree and ADAMTS13 activity levels Pedigree and ADAMTS13 activity levels Neither mutation was in the Genome Aggregation database or the ClinVar database, and they have not been previously reported. According to the ACMG guidelines, they are classified as likely pathogenic. Both of the novel mutations are predicted to be deleterious according to Mutation Taster (http://mutationtaster.org) software. Moreover, the prediction indicates that nonsense-mediated messenger RNA decay (NMD) is likely triggered by these mutations. The nonsense mutation c.2865G > A contributes to abnormal termination of translation at the 955th amino acid and results in deletion of the TSP6-8 and CUB domains. Unfortunately, an attempt to predict the mutated protein structure with the Swiss Model tool failed. The frameshift mutation c.721delG alters an amino acid and ends translation at the 7th amino acid after the mutation point, which means that the synthesized protein simply includes the signal peptide and propeptide (Fig. 4). Even if NMD is not involved, both novel mutations alter the protein structure, and protein function is impaired, promoting the occurrence of disease. Fig. 4Structure of ADAMTS13. (A) The functional domains in the ADAMTS13 protein and the locations of the mutations; SP: signal peptide, PP: propeptide; M: metalloproteinase, Dis: disintegrin, Cys: cysteine-rich, T: thrombospondin; (B) predicted structure of the wild-type ADAMTS13 protein; (C) predicted structure of the ADAMTS13 protein with the p.Gly241fs mutation Structure of ADAMTS13. (A) The functional domains in the ADAMTS13 protein and the locations of the mutations; SP: signal peptide, PP: propeptide; M: metalloproteinase, Dis: disintegrin, Cys: cysteine-rich, T: thrombospondin; (B) predicted structure of the wild-type ADAMTS13 protein; (C) predicted structure of the ADAMTS13 protein with the p.Gly241fs mutation Discussion Delayed diagnosis may account for the high morbidity and mortality associated with hTTP [10, 11]. However, there is no accurate definition of remission or acute episodes of hTTP, as severe ADAMTS13 activity deficiency persists. The diagnostic algorithm does not work well in “remission”. The misdiagnosis of hTTP as ITP is a common phenomenon. Patients with discontinuous thrombocytopenia are usually treated for ITP until an acute episode indicates TTP or even until postmortem histology is performed [12–15]. In this case, thrombocytopenia was the dominant manifestation at the onset of hTTP.Minor anaemia without schistocytes in peripheral blood smears is not always a clear enough indicator to arouse clinical suspicion. A bone marrow aspirate smear with megakaryocyte hyperplasia clearly indicated the diagnosis of ITP. Although ITP is not included in the list of differential diagnoses in the TTP guidelines [6–9], TTP in the remission period has similar characteristics to ITP [16, 17]; in contrast, ITP concurrent with intravascular haemolysis mimics TTP [18]. We propose that ITP should be included in the differential diagnosis list for TTP. Careful follow-up, detailed family history collection and further examinations should be performed when anaemia appears in patients with suspected ITP. The relationships between genotypes and phenotypes remain unclear. Here, we reported two novel mutations in ADAMTS13, c.721delG and p.Trp955X, which contributed to early-onset hTTP with thrombocytopenia and miscarriage. In a French cohort, early-onset hTTP was found to be often associated with truncated sequences and deleterious sequence variations [19]. However, in another large cohort, mutations earlier in the ADAMTS13 sequence, especially in the pre-spacer domain, were potentially related to an earlier onset and more severe manifestations of the disease [11]. The location of the enzyme activity region, metalloprotease domain and recognition domain in front of the spacer may account for the above discovery. For the patient reported here, the earlier onset at 16 years of age may be due to the prespacer mutation c.721delG. Different mechanisms, such as reduced synthesis, impaired proteolytic activity, and impaired secretion, are involved in ADAMTS13 deficiency. Nonsense mutations and frameshift mutations sometimes activate NMD, resulting in reduced ADAMTS13 activity [20]. Mutation p.Trp955X terminates the translation of the CUB and TSP domains. The CUB and TSP domains reportedly control the secretion of and conformational changes in ADAMTS13 [19–21]. We hypothesized that the proband in this case had NMD and impaired secretion of ADAMTS13, resulting in an undetectable level of ADAMTS13 activity. The presence of compound heterozygous mutations usually makes it more complicated to elucidate the relationship between the genotype and the phenotype. The presence of various triggers, such as infection, pregnancy and alcohol consumption, together determine the ultimate clinical features [22]. This is the first time that the c.721delG and p.Trp955X mutations in ADAMTS13 have been reported in hTTP, and further experiments are needed to confirm the exact pathological mechanisms involved. Plasma infusion is the first choice for the treatment of hTTP when recombinant ADAMTS13 is unavailable [7–9]. Most reports suggest starting prophylactic plasma infusion for patients with overt symptoms or chronic organ damage [11, 23]. FFP infusion at a volume of 10–15 ml/kg once every 2–3 weeks is recommended for prophylaxis [8, 9], as the ADAMTS13 half-life in plasma is 2–4 days [24]. For therapeutic purposes, the duration of plasma infusion should be determined based on the recovery of the platelet count and cessation of haemolysis, which usually takes 1–3 days [25]. For the patient reported here, plasma infusion every 2 weeks has resulted in the successful maintenance of a normal platelet count but did not ameliorate her renal injury. Prospective data from the Hereditary TTP Registry suggests that prophylactic plasma infusion is insufficient to avoid acute episodes and long-term organ damage [26, 27]. Researchers noted that some patients may benefit from PE, as it leads to increased ADAMTS13 activity and directly removes UL-VWF multimers at the same time [24]. Severe renal failure is associated with a lower level of ADAMTS13 activity [28, 29], mainly due to the deficient expression of ADAMTS13 in podocytes [30]. However, PE is not recommended, as tests for autoantibodies are negative in patients with hTTP and there can be unpredictable complications [31]. To reverse renal damage, PE was initiated in our patient, and surprisingly, immediate decreases in the creatine level and proteinuria were observed. Unfortunately, PE was disconnected as anaphylaxis with mild dyspnoea, hypotension and allergic rash occurred. Subsequent FFP infusions failed to further ameliorate the patient’s kidney function. Approaches to management during pregnancy are sophisticated. At present, most physicians agree that prophylactic FFP infusions should be started as soon as conception is confirmed, and the dosage and frequency should usually start to increase in the second trimester, a period during which TTP and foetal death are most common [32–34]. Daily FFP infusions or PE plays an important role in preventing severe episodes and premature deliveries [35]. Novel therapies such as recombinant ADAMTS13 are promising, and gene therapy is under exploration [2, 36]. Takeda’s ADZYNMA was approved by the U.S. FDA as the first and only recombinant ADAMTS13 enzyme replacement therapy for the treatment of hTTP in November 2023. In a phase III study, hTTP patients receiving prophylactic recombinant ADAMTS13 had higher ADAMTS13 activity levels than did those receiving plasma-based therapy, experienced only mild adverse events and rarely developed TTP events and manifestations [37]. Several reports have shown the successful administration of recombinant ADAMTS13 as a treatment for cTTP during pregnancy and in newborns [38–40]. It is likely that hTTP patients will be able to avoid time-consuming and expensive plasma therapy and achieve better control of the disease.